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Abstract 
Background: Patients with advanced chronic kidney disease (CKD) have high risk of sudden 
cardiac death (SCD) and may benefit from an implantable cardioverter defibrillator (ICD). 
However, the risk of ICD-related complications is also high in this population. Therefore, 
there is an unmet need for accurate risk stratification tools to identify CKD patients at risk of 
ventricular arrhythmias (VA), who may benefit from ICD implantation. This hypothesis 
generating study aimed to investigate the association between left ventricular (LV) 
mechanical dispersion and LV global longitudinal strain (GLS) measured with two-
dimensional speckle tracking echocardiography and VA and SCD in CKD patients.  
Methods: Patients with CKD stage 3b-5 (estimated glomerular filtration rate (eGFR) of  <45 
mL/min/1.73m² or on dialysis) were included and were divided in two groups according to the 
occurrence of VA or SCD during follow-up. LV mechanical dispersion, as a measure of the 
temporal heterogeneity of the LV deformation, was measured as the standard deviation of 
time to peak longitudinal strain of 17 LV segments. The ability of LV mechanical dispersion, 
LV ejection fraction and LV GLS to discriminate patients with VA or SCD during follow-up 
was evaluated using receiver operating characteristic curve analysis. 
Results: Of 250 patients (66% men, mean age 61±14 years), 16 (6%) patients experienced 
VA or SCD during a median follow-up duration of 28 months (IQR 16; 53 months). Using 
receiver operating characteristic curve analyses, LV GLS (area under the curve [AUC]: 0.79, 
95% confidence interval [CI]: 0.68-0.89) and LV mechanical dispersion (AUC: 0.71, 95% 
CI: 0.61-0.82) showed modest discrimination to identify the patients at risk of VA or SCD. In 
contrast, LV ejection fraction showed poor discrimination (AUC: 0.60, 95% CI: 0.41-0.78). 
Conclusion: LV mechanical dispersion along with LV GLS may be an additional valuable 
risk marker of VA and SCD in pre-dialysis and dialysis patients. 
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Introduction 
Patients with advanced chronic kidney disease (CKD), particularly dialysis patients, have a 
high mortality rate.1 Cardiac disease is the major cause of death and sudden cardiac death 
(SCD) is the most frequent cause.1 The enhanced arrhythmogenicity in advanced CKD 
patients is due to the increased prevalence of cardiac risk factors such as coronary artery 
disease, left ventricular (LV) hypertrophy and myocardial fibrosis, as well as non-cardiac 
(CKD-specific) risk factors such as electrolyte alterations, sympathetic hyperactivity, uremia 
and anemia.2 Patients with advanced CKD may benefit from an implantable cardioverter 
defibrillator (ICD) for prevention of SCD. However, they also show an increased risk of ICD-
related complications.3-5 Therefore, there is an unmet need for accurate risk stratification 
tools to identify CKD patients at risk of ventricular arrhythmias (VA) and SCD. LV 
mechanical dispersion and LV global longitudinal strain (GLS), measured with two-
dimensional speckle tracking echocardiography, have shown to be associated with VA in 
several cardiomyopathies.6-8 This hypothesis generating study aimed to investigate the 
association between LV mechanical dispersion and LV GLS (measured with speckle tracking 
echocardiography) and VA and SCD in pre-dialysis and dialysis patients. 
Methods 
Patient population and protocol 
In this retrospective study, pre-dialysis and dialysis patients from an ongoing registry at the 
Leiden University Medical Centre (The Netherlands) were included.9 All patients were 
diagnosed with CKD stage 3b-5 (estimated glomerular filtration rate (eGFR) of  <45 
mL/min/1.73m² or on dialysis) according to the classification of the 2012 Clinical Practice 
Guideline for the Evaluation and Management of CKD from Kidney Disease: Improving 
Global Outcomes (KDIGO).10 Patients younger than 18 years old, with inadequate 
echocardiographic image quality for off-line analysis or with limited echocardiographic 
examination, were excluded. From the departmental cardiology information system (EPD-
vision; Leiden University Medical Centre, Leiden, The Netherlands) and electronical medical 
records (HiX; ChipSoft, Amsterdam, The Netherlands), clinical data (demographics, 
cardiovascular risk factors, medication use and laboratory results) were collected and 
retrospectively analysed. eGFR was calculated by the CKD Epidemiology Collaboration 
(CKD-EPI) equation.10 Residual renal function in dialysis patients was calculated using the 
pre-dialysis plasma creatinine concentration and the concentration of creatinine in a 24-hour 
urine specimen.11 12 The 
current retrospective evaluation of clinically acquired data was approved by the institutional 
review board.  
Transthoracic echocardiography 
Images were obtained from two-dimensional transthoracic echocardiography with patients 
lying in the left lateral decubitus position, using commercially available systems (Vivid 7 or 
E9, General Electric Vingmed, Milwaukee, WI, USA) equipped with 3.5 MHz or M5S 
transducers. The echocardiographic data were digitally stored in cineloop format for off-line 
analysis (EchoPac 112.0.1, GE Medical Systems, Horten, Norway). Linear dimensions of the 
left ventricle were measured from the parasternal long-axis view on M-mode recordings and 
LV mass index was calculated and indexed to body surface area.13 LV ejection fraction 
(LVEF) was measured using LV end-diastolic and end-systolic volume from the apical 4- and 
2- chamber views, 13 To measure wall motion 
score index (WMSI), the LV was divided into 16 segments and the sum of the segment scores 
divided by 16 was calculated.13 Left atrial volume was measured using the disk summation 
technique in the apical 4-chamber view and indexed for body surface area.13 By measuring 
the width of the vena contracta in the parasternal long-axis view the severity of mitral 
regurgitation (MR) was graded semi-quantitatively.14 The aortic regurgitation was graded 
according to an integrative approach that includes qualitative (valve morphology, regurgitant 
jet characteristics, presence of diastolic flow reversal in descending aorta),  semi-quantitative 
(vena contracta width and pressure half time of the continuous wave spectral signal of aortic 
regurgitation jet) and quantitative parameters (effective regurgitant orifice area and 
regurgitant volume) as well as LV dimensions.14 The aortic valve stenosis grade was based 
on aortic valve area, aortic jet peak velocity and the mean transvalvular gradient measured 
according to current recommendations.15 LV diastolic parameters, including peak early 
diastolic (E) wave and late diastolic (A) wave were measured using pulsed wave Doppler 
recordings of the mitral inflow and E/A ratio was calculated. Septal and lateral e
annulus velocities were measured with tissue Doppler imaging at the septal and lateral side of 
the mitral annulus in the apical 4-chamber view.16 was calculated by 
. The  ratio as a measure of 
LV filling pressures was calculated.16 Tricuspid regurgitation (TR) gradient was measured on 
continuous wave Doppler tracings of the tricuspid valve and TR velocity was calculated.16 
Two-dimensional speckle-tracking echocardiography was used to measure LV GLS on 
standard routine grayscale images of the apical 4-, 2-chamber and long-axis views.17 LV GLS 
was derived from the average peak systolic longitudinal strain value of the 3 apical views. LV 
GLS is normally presented as negative values since it indicates the shortening of the 
myocardium relative to the original length.17 However, in the present study, the absolute 
value of LV GLS is presented. LV mechanical dispersion was measured as the standard 
deviation of time to peak longitudinal strain of 17 LV segments (including the apex) and 
represents the temporal heterogeneity of the LV deformation (Figure 1).7 The onset of Q/R 
wave on the surface electrocardiogram was considered to measure the time to peak 
longitudinal strain.7 The interobserver variability of LV mechanical dispersion measurements 
was evaluated using the Bland-Altman analysis which showed a mean bias was -6.6 ms (95% 
limits of agreement -42.5 to 29.4 ms).   
Follow-up 
The occurrence of VA or SCD during follow-up was registered through case record review. 
VA was defined as aborted cardiac arrest, documented sustained ventricular tachycardia or 
ventricular fibrillation. Ventricular tachycardia was defined as sustained when lasting longer 
than 30 seconds or requiring earlier intervention due to haemodynamic instability.18 SCD was 
diagnosed when a congenital or acquired potentially fatal cardiac condition was known to be 
present during life, or autopsy had identified a cardiac or vascular anomaly as the probable 
cause of the event, or no obvious extra-cardiac causes had been identified by post-mortem 
examination and therefore an arrhythmic event is a likely cause of death.19  
Statistical analysis 
Categorical data are presented as frequencies and percentages and continuous data as mean ± 
standard deviation and median with interquartile range (IQR), as appropriate. Patients were 
divided into two groups according to the occurrence of VA or SCD during follow-up. 
-test or Mann-Whitney U-test were used to analyse differences between the two 
groups for continuous data and chi-
appropriate. The ability of LV mechanical dispersion, LVEF and LV GLS to discriminate 
between patients with and without VA or SCD during follow-up was assessed with receiver 
operating characteristic (ROC) curves and area under the curve (AUC) was reported. 
Comparisons between ROC curves of LV mechanical dispersion, LVEF and LV GLS were 
performed with MedCalc software (version 16.2.1, Ostend, Belgium) using the method of 
DeLong et al.20 All statistical tests were two sided and a P-value of <0.05 was considered to 
indicate significance. SPSS software (Version 20.0. Armonk, NY: IBM Corp) was used to 
perform statistical analyses. ROC  
Results 
Of 250 pre-dialysis and dialysis patients (66% men, mean age 61 ± 14 years), 16 (6%) 
patients experienced VA (n=11) or SCD (n=5) during a median follow-up of 28 months (IQR 
16; 53 months). Patients presenting with VA or SCD had a lower systolic and diastolic blood 
pressure, a higher body mass index, more frequently showed peripheral artery disease, a 
higher phosphate and haemoglobin level and longer QRS duration compared to patients 
without VA or SCD during follow-up (Table 1). On echocardiography, patients with VA or 
SCD had larger LV mechanical dispersion, more impaired LV GLS and larger WMSI 
compared to their counterparts. LVEF was not significantly different between patients with 
and without VA or SCD (Table 2, Figure 2). On ROC curve analysis, LV mechanical 
dispersion and LV GLS showed modest discrimination to identify patients presenting with 
VA or SCD: AUC 0.71 (95% confidence interval 0.61-0.82) and AUC 0.79 (95% confidence 
interval 0.68-0.89), respectively. The AUC of LVEF was 0.60 (95% confidence interval 0.41-
0.78) suggesting limited discriminative value (Figure 3). The AUC and 95% confidence 
interval for WMSI was 0.74 (95% confidence interval 0.60-0.88). The AUC of LV GLS was 
significantly higher than the AUC of LVEF (P=0.016, 95% confidence interval 0.03-0.34), 
the other AUC values were not significantly different from each other.  
Discussion 
The present study demonstrated a frequency of VA and SCD of 6% in pre-dialysis and 
dialysis patients during follow-up. Interestingly, LVEF was not significantly different 
between patients with and without VA or SCD. On the contrary, LV GLS was significantly 
more impaired and LV mechanical dispersion was significantly longer among patients with 
VA or SCD as compared to patients without. LV GLS and LV mechanical dispersion showed 
modest discrimination to identify patients presenting with VA or SCD. 
SCD in CKD patients  
SCD accounts for 64% of all cardiac deaths of patients in hemodialysis.1 In non-dialysis 
advanced CKD patients, SCD accounts for 16% of all deaths.21 The association between 
CKD and SCD is multifactorial.22 From the Hemodialysis (HEMO) study including 1,745 
patients undergoing long-term hemodialysis, age, diabetes, peripheral vascular disease, 
ischemic heart disease and alkaline phosphatase were independent predictors of SCD.23 
Chronic inflammatory status also contributes to the excess risk of SCD. In the Choices for 
Healthy Outcomes In Caring for End-stage renal disease (CHOICE) cohort, which included 
1,041 incident dialysis patients, high levels of high-sensitive C-reactive protein and 
interleukin-6 were independently associated with twice the risk of SCD.24 Furthermore, 
reduced serum albumin was associated with 1.35 times increased risk of SCD. Among 1,078 
pre-dialysis patients, Caravaca et al showed that older age and increased comorbidity index 
(based on aggregation of comorbidities: mild [index 0]= no associated comorbidities, 
moderate [index 1]= 1 or 2 comorbidities and severe [index 3]= 3 or more comorbidities) 
were independently associated with increased risk of SCD whereas the use of antiplatelet 
drugs was associated with reduced risk.21 These studies did not include echocardiographic 
parameters that reflect structural myocardial changes that lead to a vulnerable myocardial 
substrate in patients with CKD and where transient triggers like ischemia and rapid 
electrolyte shifts may increase the risk of SCD and VA.22,25 Currently, LVEF is the 
echocardiographic parameter that American and European guidelines use to recommend ICD 
implantation for primary prevention of SCD in heart failure patients.19,26  
Selection of CKD for ICD implantation: role of advanced echocardiography 
The present study provides important novel information on the risk of VA and SCD in pre-
dialysis and dialysis patients. First, although  and heart failure symptoms are 
main criteria to recommend ICD implantation as primary prevention, this specific group of 
patients show relatively preserved LVEF.19 A recent study showed that 81% of hemodialysis 
patients fulfil criteria for heart failure with preserved LVEF.27 SCD accounts for 30-40% of 
cardiovascular related deaths among patients with heart failure and preserved LVEF.28 This 
highlights the need for more sensitive parameters than LVEF that may identify patients at risk 
of SCD and VA.   
LV GLS has demonstrated to be associated with SCD and VA and had incremental predictive 
value over LVEF in several cardiovascular conditions.29,30 LV GLS frequently unmasks LV 
myocardial damage that LVEF cannot detect. In patients with CKD, LV GLS may show LV 
systolic dysfunction in 30% of patients with preserved LVEF.31,32 LV GLS has been 
associated with increased extent of myocardial fibrosis in anatomopathological autopsy 
studies, as well as in patients using late gadolinium contrast-enhanced cardiovascular 
magnetic resonance imaging.33,34 Fibrous myocardial tissue intermingled with viable 
myocardium probably forms the substrate for VA. The present study showed that LV GLS 
could identify pre-dialysis and dialysis patients at risk of VA and SCD with an AUC larger 
than that of LVEF indicating that LV GLS may be a superior marker of arrhythmogenic risk.  
Furthermore, the mixture of scar or fibrous tissue within layers of viable myocardium 
enhances the degree of nonuniform anisotropy, increases the risk of electric uncoupling and 
creates areas of conduction block and slow conduction.35 This pronounced heterogeneous 
activation can be detected with 2-dimensional speckle tracking and the measurement of LV 
mechanical dispersion. The association between LV mechanical dispersion and increased risk 
of VA has been demonstrated in various populations. In 988 patients after acute myocardial 
infarction, Ersboll et al showed that each increment of 10 ms in LV mechanical dispersion 
was associated with a 1.15 times increase in the risk of VA.36 In 150 patients with 
hypertrophic cardiomyopathy, LV mechanical dispersion was independently associated with 
VA.37 Myocardial infarction patients and hypertrophic cardiomyopathy patients have 
increased myocardial fibrosis which may enhance the electrical heterogeneity of the LV 
myocardium. In the present study, LV mechanical dispersion was significantly longer in 
patients with VA or SCD during follow-up compared to patients without, probably indicating 
more areas of slow conduction in the former patients.  
Although LV mechanical dispersion could be considered a marker of LV mechanical 
dyssynchrony, since it is calculated as the standard deviation of time to peak longitudinal 
strain of 17 segments (according to the commercially available software used in this study), 
the term LV mechanical dyssynchrony is more frequently used in patients with heart failure 
who may be candidates for cardiac resynchronization therapy (which aims at resynchronizing 
the contraction of the LV). LV mechanical dispersion, as a measure of the temporal 
heterogeneity of the mechanical contraction of the LV, has been tested in a broader spectrum 
of patients who are at increased risk of VA/SCD (long-QT syndrome, acute myocardial 
infarction patients) and do not need per se a cardiac resynchronization therapy device.6-8 This 
is the first study that associates strain echocardiography parameters with VA and SCD in 
patients with advanced CKD. However, the relatively small number of patients presenting 
with events precluded us of performing multivariate analysis to investigate the independent 
association of advanced echocardiographic parameters and the occurrence of VA and SCD. 
Larger prospective studies are needed to investigate the role of strain echocardiography in 
risk stratification of SCD in patients with advanced CKD. 
Limitations 
This study has several limitations including its observational, retrospective design. Secondly, 
some of the echocardiographic measurements for chamber quantification or valve 
regurgitation were performed following previous recommendations whereas currently 
recommended 3-dimensional quantification were not systematically available.  Furthermore, 
selection of patients according to the echocardiographic image quality (allowing reliable 
speckle tracking analysis) and completeness of the echocardiographic examination may 
introduce a selection bias. The frequency of VA and SCD of 6% in our population may be 
affected by this selection bias and the retrospective design. In addition, LV GLS may have 
been influenced by loading conditions, despite the fact that echocardiography was performed 
after dialysis. Patients with atrial fibrillation were not excluded as long as the beat-to-beat 
variability allowed reliable analysis of LV GLS and LV mechanical dispersion. The present 
results cannot be applied to patients with atrial fibrillation and high beat-to-beat variability. In 
the present study, the LV apex is included in the analysis of LV mechanical dispersion with 
commercially available software. The results therefore may not be generalizable when other 
manufacturers are used. Lastly, since this study has a retrospective design it is not possible to 
make conclusions about predicting future development of VA or SCD.  
Conclusion 
LV mechanical dispersion along with LV GLS may provide additional valuable risk markers 
of VA and SCD in pre-dialysis and dialysis patients. 
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Legends 
Figure 1. -dialysis patients 
using a 17-segment model of the left ventricle. The left panel demonstrates a pre-dialysis 
patient without ventricular arrhythmia or sudden cardiac death during follow-up and left 
ventricular (LV) mechanical dispersion (MD) of 30 ms, LV ejection fraction (LVEF) of 68% 
and LV global longitudinal strain (GLS) of 21% (absolute value). The right panel shows a 
more pronounced LV MD of 72 ms, LVEF of 41% and LV GLS of 9% (absolute value) in a 
pre-dialysis patient with sustained ventricular tachycardia during follow-up.  
 
  
Figure 2. Box plots of left ventricular (LV) global longitudinal strain (GLS), LV mechanical 
dispersion (MD) and LV ejection fraction (LVEF) in pre-dialysis and dialysis patients with 
and without ventricular arrhythmia (VA) or sudden cardiac death (SCD) during follow-up. 
Absolute LV GLS was significantly lower and LV MD significantly higher in patients with 
VA or SCD compared to patients without VA or SCD during follow-
significantly differ between with and without VA or SCD during follow-up. 
 
  
Figure 3. Receiver operating characteristic curve analysis demonstrating the ability of left 
ventricular (LV) mechanical dispersion (MD), LV ejection fraction (LVEF) and LV global 
longitudinal strain (GLS) to predict ventricular arrhythmia (VA) or sudden cardiac death 
(SCD) in pre-dialysis and dialysis patients. Area under the curve and 95% confidence interval 
(CI) for LV GLS, LV MD and LVEF to discriminate between patients with and without VA 
or SCD were respectively, 0.79 (95% CI 0.68-0.89); 0.71 (95% CI 0.61-0.82); 0.60 (95% CI 
0.41-0.78). 
 
  
Table 1. Characteristics of pre-dialysis and dialysis patients with and without 
ventricular arrhythmias or sudden cardiac death during follow-up. 
Variable Patients without VA 
or SCD 
(n=234) 
Patients with VA 
or SCD 
(n=16) 
P value 
Clinical characteristics: 
Age (years) 
 
 
 
61 ± 14 
 
 
 
62 ± 15 
 
 
0.785 
 
Male gender, n (%) 
 
150 (64) 14 (88) 0.057 
Dialysis (vs. predialysis), n (%) 
 
Dialysis type (HD), n (%)¹ 
 
77 (33) 
 
56 (73) 
 
6 (38) 
 
5 (83) 
 
0.706 
 
1.000 
Dialysis vintage, (days)¹ 
 
Renal transplantation future, n (%) 
 
Systolic BP (mmHg) 
 
Diastolic BP (mmHg) 
 
Body mass index (kg/m²) 
 
NYHA class III-IV, n (%) 
 
Diabetes mellitus, n (%) 
 
Hypertension, n (%) 
 
Hypercholesterolemia, n (%) 
 
147 (51-329) 
 
87 (37) 
 
138 ± 22 
 
78 ± 12 
 
25 ± 4 
 
18 (8) 
 
64 (27) 
 
197 (84) 
 
88 (38) 
366 (109-724) 
 
4 (25) 
 
122 ± 15 
 
69 ± 10 
 
27 ± 6 
 
1 (6) 
 
6 (38) 
 
13 (81) 
 
7 (44) 
0.264 
 
0.327 
 
0.007 
 
0.006 
 
0.038 
 
1.000 
 
0.395 
 
0.727 
 
0.624 
Previous MI, n (%) 
 
49 (21) 7 (44) 0.057 
Previous CABG/PCI, n (%) 
 
Peripheral artery disease, n (%) 
 
Medications: 
50 (21) 
 
37 (16) 
 
 
7 (44) 
 
6 (38) 
 
 
0.059 
 
0.038 
 
 
ACE inhibitor/ARB, n (%) 
 
-blocker, n (%) 
150 (66) 
 
134 (59) 
7 (44) 
 
13 (81) 
0.075 
 
0.076 
    
Calcium antagonist, n (%) 
 
94 (41) 5 (31) 
 
0.432 
 
Laboratory results:  
                                                                                         
RRF (ml/min/1.73m²)¹ 
 
eGFR CKD-EPI (mL/min/1.73m²)² 
 
Creatinine (umol/L)² 
 
Urea (mmol/L) 
Corrected calcium (mmol/L) 
 
Phosphate (mmol/L) 
 
Parathyroid hormone (pmol/L) 
Albumin (g/L) 
Hemoglobin (mmol/L) 
Electrocardiogram: 
QRS duration (ms)                       
Corrected QT interval (ms) 
5.5 (2.5-9.2) 
 
18 ± 7 
 
314 ± 114 
 
22 ± 7 
 
2.2 ± 0.1 
 
1.4 ± 0.3 
 
16 (8-25) 
 
41 ± 6
 
7.2 ± 1.0 
 
 
107 ± 25 
 
421 ± 35 
 
3.6 (0.0-8.6) 
 
16 ± 5 
 
352 ± 132 
 
23 ± 6 
 
2.3 ± 0.1 
 
1.6 ± 0.5 
 
21 (17-22) 
 
43 ± 5 
 
7.7 ± 0.5 
 
 
137 ± 41 
 
443 ± 50 
 
0.501 
 
0.257 
 
0.315 
 
0.533 
 
0.192 
 
0.046 
 
0.198 
 
0.256 
 
0.001 
 
 
0.010 
 
0.100 
¹Measured only in dialysis patients.² Measured only in predialysis patients. 
ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; BP, blood 
pressure; CABG, coronary artery bypass graft; CKD-EPI, chronic kidney disease 
epidemiology collaboration; eGFR, estimated glomerular filtration rate; HD, hemodialysis; 
MI, myocardial infarction; MS, milliseconds; NYHA, New York Heart Association; PCI, 
percutaneous coronary intervention; RRF, residual renal function; SCD, sudden cardiac 
death; VA, ventricular arrhythmia.  
Continuous data are presented as mean ± SD or median (interquartile range). Categorical data 
are presented as numbers and percentages. 
 
 
 
 
 
 
Table 2. Echocardiographic characteristics of pre-dialysis and dialysis patients with and 
without ventricular arrhythmias or sudden cardiac death during follow-up. 
Variable Patients without VA or 
SCD 
(n=234) 
Patients with VA or 
SCD 
(n=16) 
P value 
LVEDV (ml) 
 
LVESV (ml) 
 
LV mass index (gm/m²) 
 
LVEF (%) 
 
Wall motion score index  
 
LAVI (mL/m²) 
 
Moderate/severe MR, n (%) 
 
Moderate/severe AR, n (%) 
 
Moderate/severe AS, n (%) 
 
E/A ratio 
 
 ratio 
 
TR velocity (m/s)
 
LV GLS (%) 
 
LV mechanical dispersion (ms) 
 
110 ± 47 
 
50 ± 39 
 
115 ± 36 
 
57 ± 14 
 
1.0 (1.0-1.0) 
 
28 ± 15 
 
31 (13) 
 
14 (6) 
 
18 (8) 
 
1.0 ± 0.6 
 
15 ± 10 
 
2.6 ± 0.4 
 
15 ± 5 
 
52 (43-65) 
155 ± 102 
 
89 ± 91 
 
128 ± 40 
 
51 ± 23 
 
1.3 (1.0-1.8) 
 
30 ± 12 
 
4 (25) 
 
1 (6) 
 
2 (13) 
 
1.2 ± 0.6 
 
19 ± 8 
 
2.5 ± 0.4 
 
10 ± 4 
 
66 (55-74) 
0.101 
 
0.109 
 
0.195 
 
0.281 
 
<0.001 
 
0.560 
 
0.253 
 
1.000 
 
0.373 
 
0.172 
 
0.097 
 
0.470 
 
<0.001 
 
0.004 
AR, aortic regurgitation; AS, aortic stenosis; GLS, global longitudinal strain; LAVI, left atrial 
volume index; LV, left ventricular; LVEDV, left ventricular end diastolic volume; LVEF, left 
ventricular ejection fraction; LVESV, left ventricular end systolic volume; MR, mitral 
regurgitation; SCD, sudden cardiac death; TR, tricuspid regurgitation; VA, ventricular 
arrhythmia. 
Continuous data are presented as mean ± SD or median (interquartile range). Categorical data 
are presented as numbers and percentage. 
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